Theories and determinants of self-care and self-efficacy in inflammatory bowel diseases: A systematic review.

Patient Educ CounsMay 31, 2026 (epub)
Clinical ResearchGastroenterology

Daniele Napolitano, Mattia Bozzetti, Simone Amato et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated theories and determinants of self-care and self-efficacy in patients with inflammatory bowel disease (IBD). Thirteen studies were analyzed, revealing diverse theoretical frameworks and key determinants such as psychological factors and health literacy. The review concluded that self-care behaviors correlate with improved clinical outcomes and health-related quality of life.

Key findings

  • No single theory fully explains self-care in IBD, with frameworks like Riegel's and Self-Determination Theory identified.
  • Key determinants of self-care include psychological factors, relational aspects, and personal factors.
  • Self-care behaviors are associated with more favorable clinical outcomes and improved health-related quality of life.

Why it matters

Understanding the determinants of self-care and self-efficacy in IBD is crucial for developing effective, patient-centered interventions that can enhance patient outcomes and quality of life.

Source

PubMed · PMID 42235365

Published in Patient Educ Couns. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.